Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax in Relapsed/Refractory Hodgkin's Lymphoma
NCT00359892Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2006
- Primary completion
- Sep 2007
- Countries
- 1
- Sponsor
- Gemin X Pharmaceuticals
- Modality
- Small Molecules
- Drugs
- obatoclax
- Conditions
- Hodgkin lymphoma (HL)
01
Overview
Phase 2, open-label, single-arm trial of obatoclax in Hodgkin lymphoma (HL), sponsored by Gemin X Pharmaceuticals. Primary endpoints: Response Rate, Safety Profile and 2 more. Started Jul 2006; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Obatoclax Mesylate
Obatoclax Mesylate 60mg administered as a 24-hour infusion every 2 weeks
03
Who it enrols
Patients with relapsed or refractory Hodgkin's Lymphoma who have failed at least one prior line of combination therapy and are not candidates for stem cell transplant.
04
Endpoints
Primary
Response Rate
Safety Profile
Pharmacokinetic Parameters
Pharmacodynamic Response
Beyond the preview
Go deeper on NCT00359892.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00359892.